GMAB Live signals | Maximize Profits with Getagraph.com

BUY 94804 min ago

@ $27.58

Issued: 14 Feb 2024 @ 13:11

Return: 4.06%

Previous signal: Feb 13 - 15:32

Previous signal: Sell

Return: 4.31 %

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Stats
Today's Volume	312 835
Average Volume	582 452
Market Cap	18.76B
EPS	$0 ( 2024-02-28 )
Next earnings date	( $0.160 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	30.53
ATR14	$0.0130 (0.05%)

Volume Correlation

Long: 0.31 (neutral)

Short: 0.69 (moderate)

Signal:(63.427) Neutral

Genmab A/S Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Genmab A/S Correlation - Currency/Commodity

0.20
( neutral )

0.28
( neutral )

0.00
( neutral )

0.22
( neutral )

0.55
( weak )

0.30
( neutral )

Genmab A/S Financials

Annual	2023
Revenue:	$16.47B
Gross Profit:	$15.92B (96.64 %)
EPS:	$66.64

Q4	2023
Revenue:	$4.68B
Gross Profit:	$4.55B (97.31 %)
EPS:	$9.80

Q3	2023
Revenue:	$4.74B
Gross Profit:	$4.64B (97.89 %)
EPS:	$32.60

Q2	2023
Revenue:	$4.20B
Gross Profit:	$4.20B (100.00 %)
EPS:	$20.80

Financial Reports:

No articles found.

Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.